
Roche’s Actemra/RoActemra is aimed at patients receiving systemic corticosteroids who require extracorporeal membrane oxygenation, mechanical ventilation, or supplemental oxygen.

Roche’s Actemra/RoActemra is aimed at patients receiving systemic corticosteroids who require extracorporeal membrane oxygenation, mechanical ventilation, or supplemental oxygen.

The eye drop treats age-related blurry near vision in adults and is FDA-approved for once-daily administration.

Lumateperone (Caplyta) is used for the treatment of schizophrenia and bipolar depression.

Valtrex is a nucleoside analogue DNA polymerase inhibitor that can treat herpes virus infections.

OTC sleep aids may help treat an occasional sleepless night.

Evidence indicates that low-dose tramadol is a generally safe, effective, and fast-acting antidepressant for a substantial number of individuals suffering from depression.

Pharmacy workflow changes in the preparation of chemotherapy products can reduce patient chair time.

The value of a patient-first approach and telehealth for addressing the complex health care coordination needs of patients with rare pulmonary diseases has never been more critical than during the COVID-19 pandemic.

Ruxolitinib (Opzelura; Incyte) is a Janus kinase inhibitor indicated for patients 12 years of age or older whose atopic dermatitis is inadequately controlled with topical prescription therapies or when those therapies are inappropriate.

The entire pharmacy profession and all those interested in medication safety need to coalesce around the need for systemic change in community pharmacy workplace environments.

Fremanezumab-vfrm is the second FDA-approved preventive migraine treatment that works by blocking the activity of calcitonin gene-related peptide.

Ten quiz questions to assess your knowledge on antipsychotic medications.

Lipitor is an inhibitor of HMG-CoA reductase indicated as an adjunct therapy to diet to treat high cholesterol and triglyceride levels.

Lidocaine is a local anesthetic that offers temporary relief of pain and itching.

Will expansions in scope of authority stick, or have the effectiveness and speed of pharmacy adoption of services moved the medical establishment to battle stations?

With therapeutics developing quickly in the cardiovascular space, pharmacists are more important than ever.

Pharmacy Times spoke with Dave Dixon, PharmD, to learn more about his presentation titled “New Pharmacologic Therapies for Heart Failure.

George MacKinnon, PhD, MS, RPh, FASHP, FNAP, discussed how a multi-pronged approach to burnout is necessary in the pharmacy environment.

Sirolimus is the first topical treatment to gain FDA approval for facial angiofibroma associated with tuberous sclerosis complex.

Oncology and specialty treatments advance alongside care.

Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin being evaluated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Session at American College of Cardiology Scientific Sessions 2022 highlight treatments for symptomatic obstructive hypertrophic cardiomyopathy.

Axicabtagene ciloleucel (Yescarta) approved for patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

Vaxneuvance was previously granted FDA Priority Review and Breakthrough Therapy designation for the prevention of invasive pneumococcal disease.

Tolterodine Tartrate (Detrol LA) is an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Biotene provides relief from the symptoms of dry mouth, such as bad breath, stickiness in the mouth, and chapped lips.

Mark Svet, MD, is the lead study author on a sub-analysis of the VOYAGER PAD study evaluating data on the use of rivaroxaban in patients with peripheral artery disease (PAD) and chronic kidney disease (CKD).

Multiple approaches can be taken to optimize medical therapy in patients with PAD.

Pharmacy Times spoke with Dipti Itchhaporia, MD, the 70th president of the American College of Cardiology (ACC).

Despite the approval of exciting new therapies for heart failure, there are still some challenges that need to be addressed to improve patient outcomes.